We have launched $1.3bn in new funds to back Europe’s best founders! 🎉 25 years since Balderton’s inception, we remain as excited as ever about the technological innovation and opportunity coming out of Europe. The $615 million early fund and $685 million growth fund marks our largest fundraise to date – making this the largest combined early and growth fund focussed on Europe since the start of 2022. Here’s to many more years of partnering with the European founders who are world-changing companies. Read more about here 👇 https://lnkd.in/er2tKaEb
Balderton Capital
Venture Capital and Private Equity Principals
London, London 65,413 followers
Balderton is a multistage venture firm with more than two decades of experience supporting Europe’s best founders.
About us
Balderton Capital is a multistage venture firm with more than two decades of experience supporting Europe’s best founders from Seed to IPO. We have both early and growth funds and invest across the technology sector.
- Website
-
http://www.balderton.com
External link for Balderton Capital
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 51-200 employees
- Headquarters
- London, London
- Type
- Partnership
- Founded
- 2000
- Specialties
- Venture Capital, Technology, AI, and Fintech
Locations
-
Primary
28 Britannia Street
London, London WC1X 9JF, GB
Employees at Balderton Capital
-
Rob Moffat
Partner at Balderton Capital. We are a multistage venture firm with 25 years of experience supporting Europe’s best founders from Seed to IPO.
-
Leah Sutton
Chief Portfolio Talent Officer, LP at Operator Collective
-
David Thevenon
General Partner at Balderton Capital
-
Lars Fjeldsoe-Nielsen
Growth hacker, Investor, board member and malaria fighter
Updates
-
Balderton Capital reposted this
Hey everyone! 🛸 We are excited to share that Tilt has successfully raised an $18M Series A funding round, with Balderton Capital at the forefront, joined by TQ Ventures, Earlybird, and Seedcamp. This significant investment will fuel our continuous innovations within the fashion sector. If you want to be a part of pioneering the realm of real-time shopping then reach out to me directly to explore roles in engineering, marketing, operations, and business development. A big thank you to TechCrunch, our dedicated team, investors, loyal users, and sellers for amplifying this major milestone. https://lnkd.in/exP4uc3a #funding #SeriesA #innovation #ecommerce #teamwork #shopping
-
We're so excited to announce our investment in Tilt 🛍️ From changing the way we bank at Revolut, co-founders Neil Shah and Abhi Thanendran are now on a mission to change the way we shop: helping sellers sell faster and making the experience more fun for buyers. Read more here 👇 https://lnkd.in/eYxsvdkj
Tilt raises $18M Series A to build on its real-time shopping app's success | TechCrunch
https://techcrunch.com
-
Spotted across the Atlantic 👀 Big thanks to our friends at the NYSE!
-
Balderton General Partner Suranga Chandratillake joined Tom Mackenzie on Bloomberg TV this morning to discuss our latest fundraise, why we're so passionate about Europe's entrepreneurship scene and where we see the opportunity in generative AI. "The interesting thing about Europe - being made up of multiple countries, multiple cities, you actually find different specialisms in different areas all the time."
-
Excited to see Suranga Chandratillake on CNBC with Dan Murphy this morning to discuss our new funds, our founder focus, and the exit market looking ahead 🎉 📺 👀
-
Many thanks to Lord Spencer Livermore of the HM Treasury for his kind words on today's announcement. Read more about our $1.3bn in new funds here: https://lnkd.in/eHciPi7B
-
Congratulations to the whole Healx team on this milestone moment 🎉
It's truly a pivotal time for our team. We're proud to announce two significant updates: • We raised $47 million in a Series C financing round. • The U.S. FDA has cleared our IND application to advance HLX-1502 in Phase 2 clinical trial in Neurofibromatosis Type 1 (NF1). The Series C financing was co-led by R42 Group and Atomico Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners. Proceeds of the financing will be used to advance our rare oncology, renal and neurodevelopmental disorders pipeline which includes our lead program targeting #NF1, a rare genetic condition that causes tumours to grow along the nerves. With this IND clearance, we plan to initiate the Phase 2 clinical trial for HLX-1502 by the end of 2024. Read more about today's announcements here: https://lnkd.in/eJmXb5Wy
-
This week Writer introduced two new specialised models Palmyra-Med and Palmyra-Fin to meet the demands of the highly regulated healthcare and financial sectors 👨⚕️💼 Tune into Suranga Chandratillake's chat with Writer's CEO and co-founder May Habib to learn more about how the company addresses enterprises' AI needs, the challenges around building an interface people actually want to use, and how to build the right team to take these challenges on. Catch the full conversation here 👇 https://lnkd.in/eCdE_6ic
-
Balderton Capital reposted this
🚀 Big News! 🚀 🎉 We’re thrilled to announce that Checkly has secured $20 million in Series B funding! This milestone marks a significant step in our mission to enable engineers to detect and resolve issues 10x faster. 🔎 In addition, we’re excited to introduce Checkly Traces - a feature that provides a clear, immediate view of your traces in every synthetic check run, both on the backend and frontend. ✅ With Checkly Traces, engineers can quickly connect backend failures to specific problems without the hassle of manually digging through numerous traces. Learn more about our latest funding round in this TechCrunch article: https://lnkd.in/gpdb3dnV
Checkly tests software by mimicking the way people use it | TechCrunch
https://techcrunch.com